Spectral Medical (TSX: EDT) posts C$2.44m revenue as PMA submission slips to May 2026 and derivative liabilities widen the reported loss
Oxford Biomedica (LSE: OXB) delivers first EBITDA profit as revenue surges 33% and BMS CAR-T deal signals commercial maturity
Read More 3 minute read Pharma Industry News Biocon faces regulatory heat as USFDA flags critical issues at its Bengaluru facility In a significant development that has sent shockwaves through the biotechnology industry, Biocon Ltd. has come under fire… byPallavi MadhirajuSeptember 30, 2024